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ABSTRACT
Designing a new drug is a lengthy and expensive process. As the
space of potential molecules is very large (1023 − 1060), a com-
mon technique during drug discovery is to start from a molecule
which already has some of the desired properties. An interdisci-
plinary team of scientists generates hypothesis about the required
changes to the prototype. In this work, we develop an algorithmic
unsupervised-approach that automatically generates potential drug
molecules given a prototype drug. We show that the molecules gen-
erated by the system are valid molecules and significantly different
from the prototype drug. Out of the compounds generated by the
system, we identified 35 FDA-approved drugs. As an example, our
system generated Isoniazid – one of the main drugs for Tuberculo-
sis. The system is currently being deployed for use in collaboration
with pharmaceutical companies to further analyze the additional
generated molecules.
KEYWORDS
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Medicine
1 INTRODUCTION
Producing a new drug is an expensive and lengthy process that
might take over 500 million dollars and over 10–15 years. The first
stage is drug discovery, in which potential drugs are identified
before selecting a candidate drug to progress to clinical trials. Al-
though historically, some drugs have been discovered by accident
(e.g., Minoxidil and Penicillin), today more systematic approaches
are common. The most common method involves screening large
libraries of chemicals in high-throughput screening assays (HTS)
to identify an effect on potential targets (usually proteins). The goal
of such a process is to identify compounds that might modify the
target activity, which might often result in a therapeutic effect.
While HTS is a commonly used method for novel drug discovery,
it is common to start from a molecule which already has some of
the desired properties. Such a molecule, usually called a “proto-
type”, might be extracted from a natural product or a drug on the
market which could be improved upon. Intuitively, producing a
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chemically and structurally related substance to an existing active
pharmaceutical compound usually improves on the efficacy of the
prototype drug – reduces adverse effects, works on patients that
are resistant to the prototype, and might be less expensive [7].
During this process of prototype-based drug discovery, an in-
terdisciplinary team of scientists generates hypothesis about the
required changes to the prototype. One might consider this pro-
cess as a pattern recognition process – chemists, through their
work, gain experience in identifying correlations between chemical
structure retrosynthetic routes and pharmacological properties [30].
They rely on their expertise and medicinal chemistry intuition to
create chemical hypotheses, which have been shown to be biased
[29]. However, the chemical space is virtually infinite – the amount
of synthetically valid chemicals which are potentially drug-like
molecules is estimated to be between 1023 − 1060 [27]. In this work,
we develop an algorithmic unsupervised approach to automatically
generate potential drug molecules given a prototype drug.
It is common to encode molecular structures into SMILES no-
tations (simplified molecular-input line-entry system) that pre-
serves the chemical structural information. For example, Methyl
isocyanate can be encoded using the following string: CN=C=O.
We learn embeddings of drug-like molecules in molecule space
represented by SMILES. To identify drug-like molecules, which
are used to train our algorithm, we use the Lipinski criteria – a
common chemical drug-design qualitative measure that estimates
the structure bioavailability, solubility in water, potency, etc. [22]
Variational Auto Encoders (VAE) [18] are encoder-decoder ar-
chitecture that attempts to learn the data distribution in a way that
can later be sampled from to generate new examples. State-of-the-
art results have been shown for generating images that resemble
natural images, yet not identical to the train data [18, 21]. Training
a vanilla VAE on drug-like molecules provides an ability to sample
new molecules which intuitively should be drug-like [10]. In this
work, we extend VAE to allow a conditional sampling – sampling
an example from the data distribution (drug-like molecules) which
is closer to a given input. This allows sampling molecules closer
to a prototype drug, and thus increase probability of generating
a valid drug with similar characteristics. Additionally, we add a
diversity component that allows the sampling to be different from
the prototype drug as well. We present a deep-learning approach
which we call Conditional Diversity Networks (CDN), which al-
lows the diverse conditioned sampling. The results show that the
molecules CDN generates are similar to the prototype drugs yet
significantly diverse. We show empirical results that the system
generates high percentage of valid molecules. Additionally, we per-
form retrospective experiments and use drugs developed in the
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Orciprenaline,	also	known	as	
metaproterenol,	is	a	bronchodilator	
used	in	the	treatment	of	asthma.	
Orciprenaline	is	a	moderately	
selective	β₂	adrenergic	receptor	
agonist.
Orciprenaline
Isoproterenol,	is	a	medication	used	
for	the	treatment	of	bradycardia,	
heart	block,	and	rarely	for	asthma.	
In	humans,	it	is	a	non-selective	β	
adrenoreceptor	agonist	
that	is	the	isopropylamine	analog	
of	epinephrine.
Isoproterenol
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Isoniazid	is	an	antibiotic	used	for	the	
treatment	of	tuberculosis.	For	
active	tuberculosis	it	is	often	used	
together	with	rifampicin,	
pyrazinamide,	
and	either	streptomycin	or	
Ethambutol.
Isoniazid
Pyrazinamide	is	a	medication	used	to	
treat	tuberculosis.	For	active	
tuberculosis	it	is	often	used	together	
with	rifampicin,	isoniazid,	and	either	
streptomycin	or	ethambutol.
Pyrazinamide
G
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86
Also	known	as	5-aminosalicylic	
acid	(5-ASA),	is	an	aminosalicylate	
anti-inflammatory	drug	used	to	
treat	inflammatory	bowel	disease,	
including	ulcerative	colitis,	or	
inflamed	anus	or	rectum,	and	to	
maintain	remission	in	Crohn's	
disease.
Mesalazine
4-Aminosalicylic	acid	is	an	antibiotic	
primarily	used	to	treat	tuberculosis.	
Specifically	it	is	used	to	treat	active	
drug	resistant	tuberculosis	
together	with	other	
antituberculosis medications.
Aminosalicylic
Acid
Figure 1: Drug development timeline, with example of drugs
generated by CDN (bottom), using FDA approved drugs as
prototypes (top).
1930’s and 1940’s as prototypes. The system was then able to gen-
erate new drugs, some of which discovered dozens of years after
the prototype discovery (Figure 1).
One such example is the system discovery of the main drug for
Tuberculosis – Isoniazid. Discovered in 1952, it is on the World
Health Organization’s List of “Essential Medicines, the most ef-
fective and safe medicines needed in a health system” [26]. In the
retrospective experiment, we used as prototypes only drugs discov-
ered until 1940. For the drug Pyrazinamide, first discovered in 1936,
the system generated the SMILES notation of what today is known
as Isoniazid. Pyrazinamide, although discovered in 1936, was not
used until 1972 for treating Tuberculosis. Tuberculosis can become
resistant to treatment if Pyrazinamide is used alone and therefore is
always used in combination with Isoniazid and others. The combi-
nation reduces treatment time from 9 months to less than 3 months.
This example shows promise on how substances that could not be
used at the time of discovery can serve as a prototype for discov-
ering new drugs. In collaboration with pharmaceutical companies
additional generated molecules are being tested today. We believe
our system lays the foundations to build algorithmically-directed
HTS based on prototype drugs.
2 RELATEDWORK
Over the past decade, deep neural networks (DNN) has been a game
changer in various areas of machine learning research, such as com-
puter vision [19, 34], natural language processing [24] and speech
recognition [12]. Deep neural network most prominent success sto-
ries are observed in domains with access to large, raw (unprocessed)
datasets. In such scenarios deep learning was able to achieve above
human level performance. Compared with those domains, DNN in
chemistry relies heavily on engineered features representing a mol-
ecule [4, 23, 28]. Such approaches are semi optimal as they restrict
the space of potential representations through the assumptions
made by limiting to the chosen features [9].
More recent methods overcome this issue by leveraging ad-
vanced deep neural network models to learn chemical continu-
ous representations (i.e., embeddings) based on a large datasets of
molecular raw data. Molecular raw data can be represented in few
ways, and processed with different deep architectures. Among those
we can find 2D/3D images served as input to a convolutional neural
network (CNN) [9, 35], molecular graph representation paired with
neural graph embedding methods [5, 39], and SMILES strings –
modeled as a language model with recurrent neural network (RNN)
[2, 10, 31]. Coley et al., Jin et al., Schwaller et al. leverage the em-
beddings for numerous supervised prediction task, e.g. predicting
outcomes of complex organic chemistry reactions.
Recently, deep generative models have opened up new avenues
for leveraging molecular embeddings for unsupervised tasks such
as molecule generation, and drug design. Most methods aim at
generating valid molecules. For example Segler et al. train RNN as
a language model to predict the next character in a SMILES string.
After training, the model can be used to generate new sequences
corresponding to new molecules. Gómez-Bombarelli et al. lever-
age on the VAE [18] generative model, to learn dense molecular
embedding space. At test time, the model is able to generate new
molecules from samples of the prior distribution enforced on the
latent representation during training. In this general form of gener-
ation, we can only hope to achieve the task of generating molecule
libraries with no specific chemical/biological characteristics, but
the characteristics of the training data. Others extend this approach
by tuning the model on a dataset of molecules with specific char-
acteristics [32], or by applying post processing methods, such as
Bayesian Optimization [10, 13] and Reinforcement Learning [25].
In this work, we target the problem of generating drug-like
molecules and show that training vanilla generative models on
this family shows limited results (Section 5), both for generating
diverse novel molecules and for generating drugs. Following the
common chemical approach, we focus the generative approach on
a given prototype. This helps “guide” the search process around the
prototype in the chemical space. Given prototypes can be drug-like
molecules or known drugs. We introduce parametrized diversity
and design an end-to-end neural network solution to train the
model to represent the chemical space, and to allow for further
diversity driven prototype based exploration and novel molecule
generation.
3 METHODS
We define the problem of prototype-driven hypothesis generation
as a conditional data generation process. The model operates on
a given molecule prototype and generates various molecules as
candidates. The generated molecules should be novel and share
desired properties with the prototype. The main contribution of our
work is enabling prototype-based generation with a diversification
factor. We start by reviewing how molecules are represented as text
(Section 3.1) and then present a generative model (Section 3.2). Our
generative model builds upon recent methods for deep representa-
tion learning. We train a stochastic neural network to learn internal
molecule representation (embedding). After obtaining the molecule
embedding we further utilize the stochastic component of the neu-
ral architectures to introduce parametrized diversity layer into the
generation process. The architecture of our proposed solution is
presented in Section 3.3.
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3.1 Molecule Representation
The choice of representation of molecules is at the heart of any
computer-based chemical analysis. For molecule generation, it is
of crucial importance, as the task is to both analyze and generate
objects of the same representation. Cadeddu et al. showed that
organic molecules contain fragments whose rank distribution is
essentially identical to that of sentence fragments. The consequence
of this discovery is that the vocabulary of organic chemistry and
human language follow very similar laws. Intuitively, there is an
analogy between a chemist understanding of a compound and
a language speaker understanding of a word. This introduces a
potential to leverage recent advances in linguistics-based analysis,
and deep sequence models in particular.
A SMILES string is a commonly-used text encoding for organic
molecules. SMILES represents a molecule as a sequence of charac-
ters corresponding to atoms as well as special characters denoting
opening and closure of rings and branches. For example c and C
represent aromatic and aliphatic carbon atoms, O represents oxy-
gen, -, = and # represent single, double and triple bonds [36]. Then
a molecules, such as Benzene, is represented in SMILES notation
as c1ccccc1. It has already been shown that SMILES representation
of molecules has been effective in chemoinformatics [2, 10, 31, 32].
This has strengthened our belief that recent advances in the field of
deep computational linguistics and generative models might have
an immense impact on prototype based drug development.
3.2 Molecule Driven Hypothesis Generation
Generative models have been applied for many tasks, e.g., image
generation. The models synthesized new images which resembled
the database the models were trained on [18, 21]. One of the most
popular generative frameworks are Variational Autoencoders (VAE)
[18]. VAE are encoder-decoder models that use a variational ap-
proach for latent representation learning. Intuitively, the encoder
is constrained to generate latent representations that follow a prior.
During generation, latent vectors are sampled from the priors and
passed to the decoder that generates the new representation. We
leverage VAE for the task of molecule generation. The stochasticity
allows integrating chemical diversity into the generation process.
However, application of generative models for molecule generation
have shown limited results [10]. Unlike image generation, where
each image is valid, when we aim at molecule generation, not each
representation is a valid molecule representation. Intuitively, when
we sample from the prior for image generation – the space of im-
ages is much more dense than that of valid molecules. Therefore,
many image samples are valid compared to randomly generated
molecules representations. We hypothesize that a constrained gen-
eration next to a known prototype, rather than a non-constrained
sampling, will yield better molecule generation.We extend VAE gen-
eration process to condition on a prototype, i.e., generate molecules
closer to a given drug. Intuitively, directing the sampling process
closer to existing prototype drugs might yield valid molecules that
carry similar characteristics to the the prototype yet provide diver-
sity. Our results provide evidence that a conditioned sample along
side a diversity component yields more valid and novel results. If
conditioned on known drugs, the system is able to generate drugs
discovered years after the prototype (Section 3.2).
More formally, we assume a moleculeM has a latent representa-
tion z that captures the main factors of variation in the chemical
space. Wemodel the covariates zi | M as Gaussians (zi ∼ N(µi ,σi )).
With the latent representation z at hand, we want to generate a
candidate molecule in a SMILES discrete form, therefore we define
the generative model yˆ | z ∼ Multi(θ ), where y is the generated
candidate, Formally:
q(z | M) =
Dz∏
i=1
N(µi = µˆi ,σi = σˆi) (1)
p(Yˆ | z) = Multi(θ = θˆ ) (2)
Where q is approximated via encoder neural network function,
applied on molecule M as input, and outputs the latent feature
parameterization (µˆ, σˆ ) of the molecule. We than sample instance
from this parametrization to obtain the final encoded output z; p
is represented via decoder neural network, applied on the mole-
cule sampled feature instance z as input, and generates the output
molecule as described below.
Generating a molecule as a SMILES string reflects multinomial
distribution over the atoms space. Each atom is represented via a
character. We form the character generation process as an iterative
process, each characteryi is generated based the the hidden encoded
representation z and the formerly generatedyi ’s. In total, the output
of this step is a string yˆi = {yˆ1, .., ˆyN }, where N is a pre-defined
maximal generation length. Formally, for a single character yi
P(yˆi | yˆ1, . . . , ˆyi−1, z) = f (si , ˆyi−1) (3)
Where yi−1 is the character embedding correspond to the last
character generated, and si is a state at step i representing the
current processed information of both the molecule latent repre-
sentation z, and the formerly generated y′is up to i-2.
Our goal is to create a molecule that is different from the origi-
nal moleculeM . Intuitively, we wish to explore the chemical space
around the moleculeM . Therefore, during generation process we in-
troduce a diversity component noising the multidimensional Gauss-
ian parameters used for sampling the hidden vector z. More for-
mally, to introduce diversity to our generation process, we instanti-
ate our encoder output parameters with a diversity layer. Intuitively,
the diversity layer outputs a noisy sample from a distribution cen-
tered as the encoder suggested, but with larger variance. This allows
us to explore the molecule space around an origin molecule, with
tune-able amount of diversity, corresponds to variability in chemi-
cal space. The diversity layer samples noisy instance according to
the encoded Gaussian parameters and a diversity parameter D.
The output of the diversity layer is a sample from a conditional
diverse distribution, described as follows:
Given the encoder outputs: vector of means µˆi and standard devia-
tions σˆi , and random noise sample n - from Gaussian distribution
with diversity parameter D - [n ∼ N(O,D)].
Diverse z = (n × σˆi ) + µˆi ∼ N(µˆi , σˆi 2 × D) (4)
We obtain instance from the diverse distribution as our final
noisy encoded representation (z) for the compoundM , used as the
base to for the decoder diversity-driven molecule generation.
We note that during training our diversity parameter D is set
to 1. Thus z instance is sampled from the non-diverse distribution
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Figure 2: CDN end-to-end neural net architecture
suggested by the computed parameters. Tuning this parameter at
generation time allow us to explore the space around the prototype.
3.3 CDN Architecture
We leverage recent advances in generative models and deep learn-
ing for natural language process (NLP) to form the prototype hy-
pothesis generation process as an end-to-end deep neural network
solution. Figure 2 presents CDN (Conditional Diversity Network)
architecture. CDN starts by encoding the molecule (in SMILES nota-
tion) using the encoder function. First, encoding each character in
the SMILES representation into its d dimensional embedding, then
applying convolutions over various substring (filter) sizes (e.g. cor-
respond to chemical substructures). A similar encoder architecture
was suggested for NLP tasks, such as sentence classification [16].
The extracted features are then concatenated and fully connected
layers are applied. The outputs of the encoder are considered as a
vector of means and a vector of standard deviations, representing
the distributions of features for the prototype. In VAE, those vectors
are then fed into a decoder. The goal is to optimize reconstruction
of the original input and constraint the representation to a known
prior. During generation, the vectors of features are sampled from
the prior distribution and their output is passed to the decoder that
generates a new representation.
We extend the VAE generation process by adding a diversity layer.
During generation, instead of sampling from the prior means and
standard deviations, we first feed a prototype. We sample from the
prototype feature distribution with parametrized diversity (Section
3.2) to form the prototype latent representation – served as input
for the decoder.
As described in section 3.2, our decoder is a sequential generator.
By generating sequentially, we form another parameter of variabil-
ity in the generated data, by introducing minor variations into the
molecule generated during generation. This is the main component
of many other works on molecule generation [6, 11, 32] to intro-
duce diversity into the generation process. We later show that our
diversity layer can introduce diversity beyond this component.
We represent our decoder as a recurrent neural network (LSTM).
The decoder receives the encoder output as its input. The encoded
representation forms the first state of the decoder. The decoder
then generates the compound sequentially (character by character)
by operating on the distribution over characters at each time step,
based on its updated state and the input character from former step.
During training, we feed the decoder with the correct next sym-
bol, even if it was predicted wrongly [37]. During generation, we
experiment with two options for generating the next symbol: one by
selecting the best scored character from distribution over symbols
(argmax), and the second is by sampling from the same distribu-
tion. By introducing sampling into the generation, we are able to
increase the amount of variability we generate during generation.
The model is trained to reconstruct the input prototype from a low
dimensional continuous representation, by minimizing a discrete
reconstruction loss. Formally, to minimize the reconstruction error
on a discrete molecule representation, we use the cross-entropy
loss, defined as:
H (y, yˆ) =
∑
yi log yˆi (5)
We note that we minimize the variational lower bound [18],
which is essentially optimizing the reconstruction error while con-
straining the latent distribution with a prior. To reconstruct syntac-
tically valid SMILES, the generative model would have to learn the
SMILES, which includes keeping track of atoms, rings and brackets
to eventually close them. In this case, the lower dimension rep-
resentation that can be reconstructed into a valid prototype, is a
highly informative representation. In other words, by minimizing
the reconstruction error, we want learn a prototype continuous
representation that captures the coordinates along the main factors
of variation in the chemical space. This representation is the base
for further diversifying the molecule generation process.
4 EXPERIMENTAL SETTINGS
In this section we provide details on the datasets, hyperparameter
setting, and the training in general. Then, we mention the methods
compared and used in our experiments.
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4.1 Model Details
CDN was trained using a Tensorflow API [1]. We use the Adam
algorithm [17] to optimize all the parameters of the network jointly,
regarding weights initialization - the atoms embedding were initial-
ized using a random uniform distribution ranging from -0.1 to 0.1,
convolution weights used truncated normal with std 0.1, all other
weights used the Xavier initialization [8], biases were initialized
with constant. To reduce overfitting, we included an early stopping
criteria based on the validation set reconstruction error. We use
exponential decay factor on learning rate, and the teacher forcing
method [37] during training. In total, table 1 presents CDN hyper
parameter configuration.
The code for our system is available over github1 for further
research in the community
Parameter Value
max molecule length 50
char embedding size 128
filter sizes 3, 4, 5, 6
number of filters 128
latent z dimension 300
batch size 64
initial learning rate 0.001
LSTM cell units 150
Table 1: CDN hyperparameter configuration
4.2 Datasets
4.2.1 Drug-like molecules database. In our work, we provide
experiments showing that CDN is capable of generating drug-like
molecules. We train our model on a large drug-like molecules data-
base and present several metrics on the generated molecules. The
ZINC database [14] contains commercially available compounds
for structure based virtual screening. In addition, the database have
subsets of ZINC filtered by physical properties. One such filter-
ing is based on Lipinski’s rule of five [22] – a heuristic method to
evaluate if a molecule can be a drug. The subset contains over 10
million unique drug-like compounds. CDN was trained on a subset
with approximately 200k drug-like compounds extracted at random
from the ZINC drug-like database. The subset was further divided
to train/validation/test sets, with 5k compounds for validation and
test sets, and the rest for training set. The subsets are used for train-
ing the model (train), evaluating hyperparameters and stopping
criteria (validation), and for method evaluation and experiments
(test).
4.2.2 Drug database. For our drug-generation experiment (Sec-
tion 5.2) we show that some of the molecules generated by CDN
are drugs which were discovered years later. The DrugBank data-
base [38] is a bioinformatics and cheminformatics resource that
combines detailed drug data with comprehensive drug target in-
formation. For retrospective experiments, we extracted a test set
of 869 FDA approved drugs from the DrugBank database. Note,
our system is not trained on drugs, but rather presented with drug
prototypes only during generation.
1https://github.com/shaharharel/CDN_Molecule
4.3 Compared Methods
As discussed in Section 2, not much work has been done in the area
of deep drug generation and specifically not on the diversity aspect
of the generation. To the best of our knowledge, the works that do
consider the task, do not aim at prototyping specific compound,
but training for unconditional molecule generation and later apply
post-processing to achieve general molecular characteristics. We
compare our methods to the state of the art models for molecule
generation on the reconstruction criteria, and further show that
our model is able to build on top of those models to apply diversity.
Specifically, we compare all following methods
(1) Seq2Seq [33] - An autoencoder architecture applied on se-
quence data for prediction of sequences. Both encoder and
decoder are recurrent neural networks (RNN). Although the
model is in general deterministic, it is able to bring stochastic-
ity (and thus novelty) into the molecules generation process
by setting the RNN decoder to sample from the distribution
over characters in every time step instead of predicting the
topmost next character. We therefore consider two baselines
– one using the Argmax method and the other utilizing the
Sampling method to reach diversity.
(2) Conv2Seq - To conform better with CDN parameter setting
that utilize on CNNs, we implement a second auto encoder
same as the previous method but with convolution encoder.
(3) VAE [18]– a vanilla implementation of VAE. This model gen-
erates new molecules from unit Gaussian random samples,
regardless of prototypes.
(4) CDN -VAE - Our diversity model on top of variational auto
encoder. D is the diversity parameter of Equation 4 The
higher the D, the higher the diversity induced. We note, that
for D = 1, the model extends VAE for a conditional setting
but without diversity.
5 EXPERIMENTS
In this section, we first conduct several experiments to determine
CDN performance in the task of reconstructing the molecular struc-
ture. We present evaluation of the trade off between the molecules
reconstruction accuracy and novelty as a function of CDN diversity
component. Additionally, we conduct several drug related experi-
ments to show CDN capabilities in the real world for generating
new drugs.
5.1 Novel Molecules Generation
Our main goal is to create novel molecules that carry similarities
to the prototype. Thus, the metric of reconstruction is an impor-
tant metric. We examine the methods on the task of prototype
reconstruction on a test set of 5k ZINC drug-like compounds. To
explicitly address the reconstruction accuracy and validity vs. the
generated molecules diversity, we measure the following metrics:
(1) Reconstruction Accuracy (Acc) - Character-level accuracy
with the input prototype served also as target.
(2) ValidMolecule Percentage (Valid) - Percentage of validmolecules.
There are several numeric validations performed onmolecules
representation to validate its correctness. We used Rdkit [20]
library to measure validity of the generated compounds.
2018,
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Model Acc Valid Novel Acc @ 1k Valid @ 1k Novel @ 1k
Seq2Seq - Argmax 0.94 0.93 0.13 - - -
Seq2Seq - Sampling 0.91 0.88 0.19 0.92 0.89 32.5
Conv2Seq - Argmax 0.92 0.85 0.14 - - -
Conv2Seq - Sampling 0.89 0.77 0.18 0.88 0.76 35.2
VAE -2 0.58 - - - -
CDN - D=1 0.91 0.89 0.19 0.9 0.89 8
CDN - D=2 0.82 0.81 0.26 0.81 0.8 66.6
CDN - D=3 0.64 0.63 0.37 0.65 0.65 227
Table 2: Evaluation of CDN and baselines for diversity and validity of generated molecules
Input Drug Input SMILES Generated Drug Generated SMILES
Aminosalicylic Nc1ccc(C(= O )O )c(O )c1 Mesalazine Nc1ccc(O )c(C(= O )O )c1
Pyrazinamide NC(= O )c1cnccn1 Isoniazid NNC(= O )c1ccncc1
Protriptyline CNCCCC1c2ccccc2C = Cc2ccccc21 Desipramine CNCCCN 1c2ccccc2CCc2ccccc21
Phenelzine NNCCc1ccccc1 Isoniazid NNC(= O )c1ccncc1
Isoproterenol CC(C)NCC(O )c1ccc(O )c(O )c1 Orciprenaline CC(C)NCC(O )c1cc(O )cc(O )c1
Pheniramine CN (C)CCC(c1ccccc1)c1ccccn1 Tripelennamine CN (C)CCN (Cc1ccccc1)c1ccccn1
Table 3: Sample of automatically generated drugs and the drug served as prototype to the generation process
(3) Novel Molecule Percentage (Novel) - A novel molecule is both
a valid molecule, and different from the prototype.
To be able to measure the molecule generation capabilities over var-
ious Gaussian samples for the same prototype compound (we want
to be able to generate several compounds related to the origin com-
pound), we also measure all the above metrics with@k notation.
In our context,@k represents that for each prototype compound,
we run CDN generation process with k instances of random noises
parametrized with diversity D. We note that to measure Novel@k ,
we count how many unique molecules generated – a novel mole-
cule is counted only once, even if it was generated with various
Gaussian samples for the prototype. The metric of Novel@k is not
normalized, thus, the semantics of this metric should be, intuitively,
interpreted as how many unique molecules were generated for a
prototype and 1000 Gaussian samples.
Table 2 presents the results of CDN and the baselines on the met-
rics above. Analyzing Acc , Valid and Novel metrics, we observe
that with diversity level of 1 (non-diverse sampling), CDN gener-
ates similar diversity to the baselines. Increasing D, significantly
increases the diversity in the generated molecules, while reduc-
ing the level of accuracy and the valid molecules rate. This result
stems from the intuition that as the representation becomes noisier,
it is harder for the model to reconstruct the original prototype.
Adressing the@k metrics, we observe CDN is able to maintain the
accuracy and validity levels with many random samples used for
generation, while generating various unique molecules for the same
prototype input, with the number of unique molecule significantly
increasing with the diversity parameter D.
5.2 Drug Generation
The main aim of this work is to generate novel molecules with
desired properties (characterized by the prototype molecule), by
searching the chemical space around the prototype. To check the
immediate benefits (i.e., without further screening the generated
2As no prototype is given, there is no reconstruction to measure
compound) of our approach to a real world task, we conduct a
retrospective experiment in the drug domain. We apply our method
on a test set of FDA approved drugs as prototypes. We note that
none of the drugs was observed in the training data, which was
composed of only drug-like molecules.
Evaluation on this task is harder since our goal is to generate
drugs, and we cannot a-priori know if the generated molecule has
the desired characteristics of a drug without further experiment-
ing with the compound. We therefore consider as gold standard
a test set of 869 approved known drugs. Although this test set is
very small in compare with the enormous molecule space, some
approved drugs are chemically similar and share similar therapeutic
characteristics, thus we hypothesize that by applying CDN on FDA
approved drugs as prototypes, we might be able to generate other
known compounds / drugs with similar characteristics.
Interestingly, targeting some existing drugs as prototypes, our
model was able to generate molecules that also appear in the FDA
approved drugs list and are closely related to the prototype, both
in the chemical aspects and by their medical use (i.e. targeting the
same biological mechanism of action). Table 3 presents a sample of
the drugs generated.
In total, we run the baselines and CDN variants over all 869 ap-
proved drugs dataset as prototypes, with 1000 Gaussian samples in
each run. Table 4 presents the number of FDA approved generated
drugs with each method. We also present the percentage those
drugs constitute from the valid molecules generated. We draw the
reader attention to the negligible chance of generating a drug using
exhaustive search without constraints (e.g., using HTS). We observe
that the VAE could not produce any known drug. We hypothesize
that this stems from the fact that VAE randomly generates a mol-
ecule and not based on a prototype. CDN with no diversity and
the other baselines generated 9–12 drugs. This result emphasize
how the variability that the decoders present during sampling con-
tributes to the generation of known drugs. More interestingly, we
observe that for higher D values of our diversity layer (CDN-VAE
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Model #Drugs % from Generated
Valid Molecules
VAE 0 0%
Seq2Seq 12 0.002%
Conv2Seq 9 0.0018%
CDN-VAE D=1 12 0.0023%
CDN-VAE D=2 22 0.005%
CDN-VAE D=3 35 0.01%
Table 4: Automatically generated FDA approved drugs. We
present the percentage of the FDA-approved drug from the
total valid molecules generated by each method
D=2 and CDN-VAE D=3), the amount of known drugs increases sig-
nificantly. One should remember that the model doesn’t have any
“drug” understanding – the model was only trained given drug-like
molecules, and all known drugs were eliminated from the training.
The key here is the chemical similarity drugs share. Thus, by tar-
geting a drug molecule as prototype to the generation process, our
model is able to chemically diversify the prototype drug in a way
that generated another known drugs. We are encouraged by the
results that CDN was able to generate a significant number of al-
ready known drugs. We are currently testing with pharmaceuticals
companies the additional generated molecules.
5.3 Qualitative Examples
We present a few qualitative examples of the drugs generated. We
would like to explore whether the application of the system on
drugs developed up until a certain year might find drugs that will
be discovered years later. During training we eliminate all known
drugs from the ZINC database and we present as prototypes a sin-
gle drug. Figure 1 presents a timeline with example pairs of origin
(top row) and generated (bottom row) molecules, with the year
of the drug first use. By using CDN we could have generated the
bottom molecules directly when we knew the origin molecules,
possibly sparing years of research. The system was able to identify
the main drug for Tuberculosis – Isoniazid using an initial pro-
totype of the disease that was never used due to its side effects
(Pyrazinamide). Additional intriguing example is the generation of
Orciprenaline which is used to treat Asthma from a prototype drug
that was mainly used for heart block, and very rarely for asthma.
These pairs are closely related in their therapeutic effect, but a few
changes for the molecule were needed to reposition it for Asthma
treatment. Another interesting discovery was Mesalazine, used to
treat inflammatory bowel disease based on an antibiotic primarily
used to treat tuberculosis. discovered about 40 years before.
5.4 Diversity Mechanisms
A common method to employ diversity in encoder-decoder models
is to employ a sampling decoder into the architecture [6, 11, 32].
The diversity is introduced by sampling from distribution over char-
acters in each time step of generation, rather than choosing the
topmost (argmax) character at test time. We analyze the contribu-
tion of the diversity layer D for CDN presented in this work along
side a sampling decoder as well. Table 5 presents CDN performance
on the previous metrics (Section 5.1), but with a sampling decoder.
We compare CDN with sampling but with no diversity component
Figure 3: Diversity parameter effect on performance.
Model Acc Valid Novel A@1k V@1k N@1k
CDN D=1 0.88 0.78 0.19 0.88 0.79 39.5
CDN D=2 0.8 0.69 0.25 0.79 0.68 94
CDN D=3 0.57 0.39 0.27 0.56 0.38 179
Table 5: CDN performance using a sampling decoder.
(D = 1) to CDN with sampling with higher values of D and observe
that the diversity parameter is able to introduce additional diversity
beyond the sampling decoder component.
To analyze the behavior of the diversity parameter D on the
accuracy/validity and novelty trade-off in the drug domain, we gen-
erated samples for the FDA approved test set (Section 4.2), with var-
ious configurations of the diversity parameter D. Figure 3 presents
the results for the two types of decoder functions. As we hypoth-
esized, with both decoders, increasing the value of the diversity
parameter D, significantly increases the amount of novel molecules
generated. As we expected, the novelty is not free, we observe lower
accuracy and lower valid rates for increased diversity. Comparing
argmax with sampling decoders, we observe that in general, sam-
pling has lower accuracy and valid rate, but for low diversity value
the sampling method generates significantly more novelty than the
argmax. This behavior reduces for higher values of the diversity
parameter, were both methods generates similar rates of novelty.
We also observe the novelty rate reduces at some point of increased
diversity value. This is quite expected because for large values of
diversity, the latent molecule representation sampled with larger
2018,
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Figure 4: Levenshtein distance histograms for analyzing the diversity generated by CDN . Top - Origin molecule vs Generated
molecule distances. Bottom - within generated molecule population distances.
noise, thus at some point the generator is not able to recover much
valid molecules in general, and novel ones in particular.
5.5 Molecular Variations
We would like to analyze not only whether a molecule is differ-
ent from the prototype molecule but also quantify the diversity
of the molecules with respect to the prototype molecule. Addi-
tionally, we would like to validate that the generated molecules
originating from a prototype are also diverse with respect to one
another. We compare the Levenshtein distances of the generated
SMILES within the generated population and with respect to the
prototype, used as input for a specific generation instance. We ap-
ply CDN on the drug-like test set as prototypes. We note that we
count only valid molecules generated in all evaluations. Figure 4
presents histograms of the Levenshtein distances for the generated
molecules, with approximated Gaussian parameters and curve on
top of the histograms. The top row represents the input prototype
compared to the generated molecules Levenshtein distance distri-
bution for different configurations of the diversity parameter D
(increasing D from left to right). The bottom row represents the
inner-generated population Levenshtein distance distribution for
various values ofD. On both type of distance evaluations (rows), we
observe significantly larger Levenshtein distances for larger values
of D, thus indicating positive effect of the diversity parameter D
on both the distance from the prototype molecule, and the aver-
age inner distance between molecules that were generated with
different random samples to the same prototype. Additionally, we
observe CDN diversity in generation is not limited to generating
diversity with respect to the origin molecule, but also generates
diversity within the generated population for a specific prototype,
with higher amount of diversity tuned with the diversity parameter
D.
Class Cosine L2 L1
Thiazide Diuretics 0.872 .95 .908
Benzodiazepines 0.923 .883 .859
β-Blocker 0.866 .849 .822
NSAIDs 0.955 .853 .833
Across Drugs 1.0 1.0 1.0
Table 6: In class and across drugs normalized distances com-
puted on various drug classes.
5.6 Molecule Representation in Latent Space
Encoder-decoder settings produce intermediate representations of
their input. In this section, we analyze the quality of those represen-
tations. During CDN generation process, we first encode molecule
into a low dimensional vector space with the encoder function. We
refer to the output vector as the molecule embedding. To evaluate
the embeddings, we leverage them for the task of drug classification.
Intuitively, if the embeddings captures enough information for drug
classification, we might rely on this representation for molecule
generation. We note that for the task of encoding the molecule
feature representation, we set the diversity parameter D = 1, but
one should remember that the representation is still instantiated
from unit Gaussian, and thus is not deterministic.
A drug class is a set of medications that have similar chemical
structures, or the same mechanism of action (i.e., bind to the same
biological target). In Table 6we report embedding vector normalized
distances in-class and across various drug classes. Thiazide and
Benzodiazepines are chemical classes while β−Blocker and NSAIDs
3 are classes representing mechanism of action. We observe all
in-classes distances are significantly lower than across class. We
conclude that although our molecule representation is noisy by the
stochastic nature of CDN , similarities in the embedding space are
able to reflect significant similarities among various drug class.
3NSAIDs - Nonsteroidal anti-inflammatory agents
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6 CONCLUSIONS
Drug discovery is the process of identifying potential molecules
that can be targeted for drugs. Commonmethods include systematic
generation and testing of molecules via HTS. However, the molec-
ular space is very large. Additional approaches require chemist to
identify potential drugs based on their knowledge. Usually, they
would start from a known compound in nature or known drug
and identify potential changes. Approaches in machine learning
today mainly focused on non-controlled molecule generation using
generative mechanisms, such as VAE. The approaches were limited
in their ability to generate both valid and novel molecules. In this
work, we presented a prototype-based approach for generating
drug-like molecules. We adopt the chemist approach of “borrowing”
from nature or focusing on known drugs. We hypothesize that bias-
ing the molecule generation towards known drugs might yield valid
molecules. We train our model on drug-like molecules, and during
generation extend VAE to, intuitively, search closer to the prototype
(which can be a drug). We add additional component to diversify the
molecules generated. We present results that show that many of the
molecules generated are both valid and novel. When conditioning
on drugs, we observe our system was able to generate known drugs
that it never encountered before. The system is currently being
deployed for use in collaboration with pharmaceutical companies
to further analyze the additional generated molecules.
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